These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38960464)

  • 1. Segmentectomy for ground glass-dominant invasive lung cancer with tumour diameter of 2-3 cm: protocol for a single-arm, multicentre, phase III trial (ECTOP1012).
    Chen S; Huang Q; Fu F; Wang Z; Zhang Y; Chen H
    BMJ Open; 2024 Jul; 14(7):e087088. PubMed ID: 38960464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
    Aokage K; Suzuki K; Saji H; Wakabayashi M; Kataoka T; Sekino Y; Fukuda H; Endo M; Hattori A; Mimae T; Miyoshi T; Isaka M; Yoshioka H; Nakajima R; Nakagawa K; Okami J; Ito H; Kuroda H; Tsuboi M; Okumura N; Takahama M; Ohde Y; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Lancet Respir Med; 2023 Jun; 11(6):540-549. PubMed ID: 36893780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211).
    Aokage K; Saji H; Suzuki K; Mizutani T; Katayama H; Shibata T; Watanabe S; Asamura H;
    Gen Thorac Cardiovasc Surg; 2017 May; 65(5):267-272. PubMed ID: 28255781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ground glass opacity resection extent assessment trial
    Li H; Wang Y; Chen Y; Zhong C; Fang W
    Front Oncol; 2023; 13():1052796. PubMed ID: 36741022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of surgical outcomes and prognosis between wedge resection and simple Segmentectomy for GGO diameter between 2 cm and 3 cm in non-small cell lung cancer: a multicenter and propensity score matching analysis.
    Zhou Y; Yu T; Zhang Y; Qian L; Xia Q
    BMC Cancer; 2022 Jan; 22(1):71. PubMed ID: 35034626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Efficacy Analysis of Wedge Resection of Pulmonary 
in Patients with Small Volume Invasive Lung Adenocarcinoma].
    Cui S; Wang G; Huang Z; Wu M; Wu H; Zhou H; Xu M; Xie M
    Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):359-366. PubMed ID: 38880923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intentional wedge resection versus segmentectomy for ≤2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting.
    Liu C; Yang Z; Li Y; Guo C; Xia L; Zhang W; Xiao C; Mei J; Liao H; Zhu Y; Lin F; Ma L; Pu Q; Liu L
    Int J Surg; 2024 Jul; 110(7):4231-4239. PubMed ID: 38518080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical outcome of wide wedge resection in poor-risk patients with clinical-N0 non-small cell lung cancer.
    Tsunezuka H; Kato D; Okada S; Furuya T; Shimada J; Inoue M
    Gen Thorac Cardiovasc Surg; 2017 Oct; 65(10):581-586. PubMed ID: 28748318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer.
    Suzuki K; Watanabe SI; Wakabayashi M; Saji H; Aokage K; Moriya Y; Yoshino I; Tsuboi M; Nakamura S; Nakamura K; Mitsudomi T; Asamura H;
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):289-301.e2. PubMed ID: 33487427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for a single-arm, multicenter, prospective, confirmatory phase III trial of wedge resection for invasive ground glass opacity-featured lung cancer with a size ≤2 cm and a consolidation tumor ratio between 0.25 and 0.5 (ECTOP-1020 study).
    Li T; Fu F; Zhang Y; Chen H
    J Thorac Dis; 2024 Jul; 16(7):4711-4718. PubMed ID: 39144343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal patient-reported outcomes 1 year after thoracoscopic segmentectomy versus lobectomy for early-stage lung cancer: a multicentre, prospective cohort study protocol.
    Gao X; Dai W; Zhang Q; Liu W; Liu Y; Yang L; Wei X; Shi Q; Pompili C; Pu Y; Xie S; Xiang R; Tian B; Hu B; Yang X; Wang X; Yang X; Xie T; Tang Y; Qiao G; Sun N; Gao S; Zhang G; Chen D; Cui Y; Chen X; He Y; Zhang R; Li Q; Zhuang X
    BMJ Open; 2023 Jan; 13(1):e067841. PubMed ID: 36657755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):637-42. PubMed ID: 24477740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial).
    Kamigaichi A; Hamada A; Tsuboi M; Yoshimura K; Okamoto I; Yamamoto N; Tsutani Y
    Clin Lung Cancer; 2024 Jun; 25(4):384-388.e1. PubMed ID: 38360496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited resection trial for pulmonary ground-glass opacity nodules: case selection based on high-resolution computed tomography-interim results.
    Yoshida J; Ishii G; Hishida T; Aokage K; Tsuboi M; Ito H; Yokose T; Nakayama H; Yamada K; Nagai K
    Jpn J Clin Oncol; 2015 Jul; 45(7):677-81. PubMed ID: 25900903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Zhang C; He Z; Cheng J; Cao J; Hu J
    Clin Lung Cancer; 2021 Mar; 22(2):e160-e168. PubMed ID: 33160898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces.
    Kagimoto A; Tsutani Y; Kushitani K; Kai Y; Kambara T; Miyata Y; Takeshima Y; Okada M
    Ann Thorac Surg; 2021 Sep; 112(3):935-943. PubMed ID: 33144104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative Recurrence and Survival After Segmentectomy for Clinical Stage 0 or IA Lung Cancer.
    Kamigaichi A; Tsutani Y; Fujiwara M; Mimae T; Miyata Y; Okada M
    Clin Lung Cancer; 2019 Sep; 20(5):397-403.e1. PubMed ID: 31281050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [JCOG lung cancer surgery trial series: review and interpretation].
    Li RZ; Qiu B
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):703-711. PubMed ID: 35880335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.